Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NYSE:CATX NYSE:INFU NASDAQ:SOLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.27+0.8%$6.96$5.81▼$14.38$601.08M0.84398,468 shs235,027 shsCATXPerspective Therapeutics$3.37-1.7%$3.75$1.60▼$16.31$250.27M1.2920,524 shs326,663 shsINFUInfuSystem$10.42+1.6%$7.79$4.61▼$11.04$209.57M1.82179,389 shs316,773 shsSOLYSoliton$22.58$21.55$7.40▼$22.60$487.66M0.19347,827 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+0.83%+0.69%+5.06%+8.35%-30.76%CATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%SOLYSoliton0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.27+0.8%$6.96$5.81▼$14.38$601.08M0.84398,468 shs235,027 shsCATXPerspective Therapeutics$3.37-1.7%$3.75$1.60▼$16.31$250.27M1.2920,524 shs326,663 shsINFUInfuSystem$10.42+1.6%$7.79$4.61▼$11.04$209.57M1.82179,389 shs316,773 shsSOLYSoliton$22.58$21.55$7.40▼$22.60$487.66M0.19347,827 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+0.83%+0.69%+5.06%+8.35%-30.76%CATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%SOLYSoliton0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.7589.13% UpsideCATXPerspective Therapeutics 3.18Buy$12.56272.57% UpsideINFUInfuSystem 4.00Strong Buy$12.5019.96% UpsideSOLYSoliton 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SOLY, BVS, CATX, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$564.14M1.07$0.58 per share12.58$2.80 per share2.60CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINFUInfuSystem$139.89M1.52$0.81 per share12.79$2.47 per share4.22SOLYSolitonN/AN/AN/AN/A$1.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23MN/AN/A15.80N/A-7.11%15.61%4.01%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)INFUInfuSystem$870K$0.23173.7033.61N/A1.12%2.78%1.41%N/ASOLYSoliton-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ASOLYSolitonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99CATXPerspective TherapeuticsN/A9.609.60INFUInfuSystem0.501.981.59SOLYSolitonN/A5.475.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%CATXPerspective Therapeutics54.66%INFUInfuSystem71.13%SOLYSoliton35.11%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%CATXPerspective Therapeutics3.52%INFUInfuSystem10.20%SOLYSoliton12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableSOLYSoliton1421.60 million19.01 millionNot OptionableSOLY, BVS, CATX, and INFU HeadlinesRecent News About These CompaniesBäcklund and Darboux TransformationsJanuary 4, 2024 | cambridge.orgCSoliton Systems Revolutionises Authentication with Soliton OneGate: Multi-Factor Authentication Enhanced by Digital CertificatesSeptember 14, 2023 | benzinga.com7 Questions for Senegalese Artist Soly Cissé on How the Rise of the West African Art Scene Is Reshaping Local CommunitiesAugust 8, 2023 | news.artnet.comNThe Direct Method in Soliton TheoryJune 28, 2023 | cambridge.orgCCould this copycat black hole be a new type of star?May 17, 2023 | hub.jhu.eduHMid-infrared Laser Market Key Drivers, Challenges, Growth and ... - Digital JournalMay 8, 2023 | news.google.comNSediment resuspension due to internal solitary waves of elevation in ... - Nature.comMay 4, 2023 | news.google.comNINRS celebrates the careers of two eminent researchers - EurekAlertMay 4, 2023 | news.google.comN39th Annual Day Function at KEC - Afternoon NewsMay 3, 2023 | news.google.comNMagnetostatic interaction between Bloch point nanospheres ... - Nature.comMay 3, 2023 | news.google.comNAcoustic stability of a self-gravitating cylinder leading to ... - Nature.comMay 3, 2023 | news.google.comNThe Top 8 Fishing Must-Haves for Any Angler - AOLMay 3, 2023 | news.google.comNFor the First Time Ever, China Tested a Stirling Engine in Space - AOLMay 3, 2023 | news.google.comNPatagonia Has Jackets for 50% Off (If You Know Where to Look) - AOLMay 3, 2023 | news.google.comNIt Looks Like a Black Hole. It Acts Like One. It Could Be Something ... - msnNOWMay 3, 2023 | news.google.comNCollege Students Came Up With a Way to Make ChatGPT Not Evil - AOLMay 2, 2023 | news.google.comNA New Study Says Gray Hair May Be Reversible - AOLMay 2, 2023 | news.google.comNThe 6th Mass Extinction Is Further Along Than We Thought - AOLMay 2, 2023 | news.google.comNA Chinese Company Says Its Batteries Are Dense Enough to Power Electric Planes. Sure. - AOLMay 2, 2023 | news.google.comNPick Up the Furbo 360° Dog Camera While It's 30% Off During Amazon's Pet Day Sale - AOLMay 2, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOLY, BVS, CATX, and INFU Company DescriptionsBioventus NYSE:BVS$7.27 +0.06 (+0.83%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$7.27 0.00 (0.00%) As of 09/9/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Perspective Therapeutics NYSE:CATX$3.37 -0.06 (-1.75%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$3.37 0.00 (0.00%) As of 09/9/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InfuSystem NYSE:INFU$10.42 +0.16 (+1.56%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$10.41 -0.01 (-0.06%) As of 09/9/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Soliton NASDAQ:SOLYSoliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
